Key statistics
On Friday, Actinium Pharmaceuticals Inc (ATNM:ASQ) closed at 1.71, 66.15% above the 52 week low of 1.03 set on Mar 04, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.65 |
---|---|
High | 1.77 |
Low | 1.63 |
Bid | 1.68 |
Offer | 1.75 |
Previous close | 1.62 |
Average volume | 217.52k |
---|---|
Shares outstanding | 31.20m |
Free float | 30.64m |
P/E (TTM) | -- |
Market cap | 50.54m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
- Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
- Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
- Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting